- Home
- SEMR vs KROS Comparison
SEMR vs KROS Comparison
Compare SEMR & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEMR
- KROS
- Stock Information
- Founded
- SEMR 2008
- KROS 2015
- Country
- SEMR United States
- KROS United States
- Employees
- SEMR N/A
- KROS N/A
- Industry
- SEMR EDP Services
- KROS Biotechnology: Pharmaceutical Preparations
- Sector
- SEMR Technology
- KROS Health Care
- Exchange
- SEMR Nasdaq
- KROS Nasdaq
- Market Cap
- SEMR 1.7B
- KROS 633.5M
- IPO Year
- SEMR 2021
- KROS 2020
- Fundamental
- Price
- SEMR $11.73
- KROS $15.92
- Analyst Decision
- SEMR Buy
- KROS Buy
- Analyst Count
- SEMR 7
- KROS 11
- Target Price
- SEMR $16.14
- KROS $68.83
- AVG Volume (30 Days)
- SEMR 407.2K
- KROS 1.9M
- Earning Date
- SEMR 11-07-2024
- KROS 02-26-2025
- Dividend Yield
- SEMR N/A
- KROS N/A
- EPS Growth
- SEMR N/A
- KROS N/A
- EPS
- SEMR 0.08
- KROS N/A
- Revenue
- SEMR $357,567,000.00
- KROS $651,000.00
- Revenue This Year
- SEMR $24.50
- KROS $224.66
- Revenue Next Year
- SEMR $20.36
- KROS N/A
- P/E Ratio
- SEMR $151.26
- KROS N/A
- Revenue Growth
- SEMR 22.01
- KROS 8037.50
- 52 Week Low
- SEMR $9.64
- KROS $15.33
- 52 Week High
- SEMR $16.42
- KROS $73.00
- Technical
- Relative Strength Index (RSI)
- SEMR 30.80
- KROS 22.66
- Support Level
- SEMR $11.85
- KROS $15.33
- Resistance Level
- SEMR $12.59
- KROS $17.25
- Average True Range (ATR)
- SEMR 0.45
- KROS 1.37
- MACD
- SEMR -0.13
- KROS -0.48
- Stochastic Oscillator
- SEMR 12.59
- KROS 10.31
About SEMR SEMrush Holdings Inc.
SEMrush Holdings Inc is engaged in the provision of an online visibility management software-as-a-service platform. Its platform enables subscribers to improve their online visibility and drive traffic, including on their websites and social media pages, and distribute highly relevant content to their customers on a targeted basis across various channels to drive high-quality traffic and measure the effectiveness of their digital marketing campaigns. Geographically, it generates revenues from the US, the UK, and other regions.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.